Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy. - Wikidata - wikimedia - TriplyDB

Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.

Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.

http://www.wikidata.org/entity/Q35659264

about

Management of HIV Infection during Pregnancy in the United States: Updated Evidence-Based Recommendations and Future Potential Practices The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs A Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women.AASLD guidelines for treatment of chronic hepatitis B.Bone health in HIV-infected children, adolescents and young adults: a systematic review.Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis.Bone health in HIV-infected children and adolescents.In Utero Tenofovir Exposure Is not Associated With Fetal Long Bone Growth.PrEP as Peri-conception HIV Prevention for Women and Men.A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy.Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa.Disclosing in utero HIV/ARV exposure to the HIV-exposed uninfected adolescent: is it necessary?Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders.Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approach Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057.Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.Complications of Treatment in Youth with HIV.Impact of maternal HIV-1 infection on the feto-maternal crosstalk and consequences for pregnancy outcome and infant health.Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.Tenofovir exposure in utero and linear growth in HIV-exposed, uninfected infants.Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus.Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi.Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines Reply to Koo et al Third-trimester tenofovir to prevent mother-to-child hepatitis B virus transmission.Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.Hepatitis B in Pregnancy.Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018.Ethical and Psychosocial Considerations in Informing HIV-Exposed Uninfected Children That They Were Exposed to HIV and Antiretroviral Medications In Utero.Efficacy and safety of nucleos(t)ide analogues to prevent hepatitis B virus mother-to-child transmission in pregnant women with high viremia: real life practice from China.Current evidence on the management of hepatitis B in pregnancy

P2860

Q26738453-479B3374-79E7-46C0-89B4-55CADAF6C66D Q26744617-9A70A93F-F8E7-48B5-B4DD-D315EC28412C Q33711399-B508745B-1B9A-4C6F-BD0A-95D68FF9C2C5 Q34501660-8CC4A22B-FAA5-4CCF-AD70-6DC9B96F6770 Q35822412-4D1EAB35-01CB-4E74-9A03-0E3435D907B9 Q35840548-D2C2F63B-BF78-49B8-B8D2-917D53DA72D2 Q36882631-5042E84E-799C-4A24-A489-F651ACBC270E Q36948111-076D3BBA-9E68-4D9F-B4A4-B6A53DDEEB7A Q36963511-1DE1FCA6-94E5-489E-AAFA-35A6FCA9CE9B Q37277571-3241424B-195F-4A7D-A3B5-886B42E181C1 Q37298218-38D6EEEE-9C87-4EC6-A2F0-0BF6BD16C7AD Q37342120-DD20B393-7FDD-4DB6-943B-8ED6ED02F9C3 Q38609568-2B96AC2A-0653-49F9-B00D-56059743B22C Q38737364-00EFB175-781A-482D-83B8-FC7F65B62683 Q38801873-04D74DE9-2C1D-449D-B5D6-450978844A1F Q38828635-A6A359D2-07AF-48AF-A89A-66904DBEB4A9 Q38846571-FEC3361D-79C7-4761-94EA-4346B9DCAA9A Q38890564-6EC3994F-5166-413B-8959-300B72E45061 Q38909409-06926485-DA49-4B76-8E5D-9F7F5943A32A Q39145435-36CFA0B5-8276-46C4-97E4-2B1F26C4330F Q39258357-B2144492-DCB3-4BE8-B05A-FABD3772DC94 Q39520236-6518950B-820D-4776-9947-A1FC61DF6A41 Q42334798-B557719B-4E81-441F-948E-656967A1BFE6 Q42399337-38FDD6D5-16CD-4906-964F-4C75FFDA959B Q45073764-84BBD38E-D867-41A7-AB8B-6E2BCB7539CE Q50190669-4B66D012-9390-4CE9-8909-1C597C7910BA Q50859070-B9CD087D-A9E6-45C7-843C-C01AD96E0518 Q52571189-8CDFDD1A-C7DD-4C42-B454-9F8CFD5C37D3 Q54574017-D8D4DE90-B6A4-45BB-9DE2-ACC06A83F15D Q55711692-756EBD70-0248-4CBB-B3B6-0BEEBC5E5125 Q57491228-900E9DCF-A82F-42F2-91D2-66C65527EA8C

P2860

Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.

http://www.wikidata.org/entity/Q35659264

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Lower Newborn Bone Mineral Con ...... xil Fumarate During Pregnancy.

@ast

Lower Newborn Bone Mineral Con ...... xil Fumarate During Pregnancy.

@en

type

label

Lower Newborn Bone Mineral Con ...... xil Fumarate During Pregnancy.

@ast

Lower Newborn Bone Mineral Con ...... xil Fumarate During Pregnancy.

@en

prefLabel

Lower Newborn Bone Mineral Con ...... xil Fumarate During Pregnancy.

@ast

Lower Newborn Bone Mineral Con ...... xil Fumarate During Pregnancy.

@en

P1433

Q35659264-E30F8D01-A93B-445F-B817-5821AFC2076C

P1476

Q35659264-E88CF44B-4812-4000-9748-017BFC1771BC

P2093

Q35659264-083048AB-955D-4524-B258-CC9BD64D12EF

Q35659264-1C0300F5-B571-4972-9D4F-77E1463DDBEA

Q35659264-2162ED66-6F2E-4EAB-AB78-3667F7656515

Q35659264-2345FD6C-0BBD-4B9D-BA69-EB1446D28715

Q35659264-58C1783C-0137-4572-8143-885D6780572A

Q35659264-6A8424FD-D124-4155-BB39-EDCFFD6833B6

Q35659264-6D7C75DB-1333-499E-A093-ACE749BC8555

Q35659264-7249FC4C-F3F9-4616-AB72-5CAB24AD712B

Q35659264-83C5B308-26BA-42F5-93A1-8F245BAC4EB9

Q35659264-94D8DF41-AB24-47D0-BFD4-07F430E27FBD

P2860

Q35659264-015E195F-745A-4147-AF32-83C10959DD15

Q35659264-0575F186-28AB-4CC1-BECB-CE84EC99A815

Q35659264-0F549316-27E1-49B3-A9E0-E71632B3ABD1

Q35659264-118508EB-FCED-428D-B761-3D19783CFECD

Q35659264-168ED6CB-7342-4704-8173-25A95EA405E4

Q35659264-1764192E-3F7D-4063-B87C-7713A179678B

Q35659264-1E8526A7-CDE6-4251-8BB0-8B90A8A81E19

Q35659264-213E92D3-6781-4395-A09C-55E77F98B20D

Q35659264-26021995-30B6-40E7-8E4E-E43A9E840F8F

Q35659264-287AD399-B6B7-4400-8734-2D1397C1E0BF

P304

Q35659264-CC2361C3-B084-4285-84A8-8BED97DD3E4B

P31

Q35659264-8670A76D-58F2-4223-90A3-20B2D7B00BF7

P356

Q35659264-9214C88E-4D18-4B7B-82D7-E9E8C8827237

P407

Q35659264-B0C3E3BE-384B-44B9-8DAC-93B047B3054E

P433

Q35659264-BA02A1C3-0963-4D80-9A40-D9314070F37F

P478

Q35659264-33E5063F-DD57-415C-8E7C-1AE2DA083A90

P50

Q35659264-F357B2CB-742F-4038-BF4B-ADB5F672D802

P577

Q35659264-8853B820-91A9-42C9-AB17-638DC99D53D1

P5875

Q35659264-B2AA0333-651A-46AD-9123-23C5AC71BED2

P698

Q35659264-8FB613EB-F901-480A-8BF1-B579B612EDD7

P921

Q35659264-E5C08201-F8C1-4890-9AB1-554D5C26C1C6

P932

Q35659264-8C48EAD9-B398-4631-BC2E-4F0E7A3A2E27

P356

P1433

Clinical Infectious Diseases

P1476

Lower Newborn Bone Mineral Con ...... xil Fumarate During Pregnancy.

@en

P2093

Denise L Jacobson

http://www.w3.org/2001/XMLSchema#string

Emily Barr

http://www.w3.org/2001/XMLSchema#string

George K Siberry

http://www.w3.org/2001/XMLSchema#string

George R Seage

http://www.w3.org/2001/XMLSchema#string

Heidi J Kalkwarf

http://www.w3.org/2001/XMLSchema#string

Julia W Wu

http://www.w3.org/2001/XMLSchema#string

Justin J Wheeler

http://www.w3.org/2001/XMLSchema#string

Katherine M Knapp

http://www.w3.org/2001/XMLSchema#string

Kenneth C Rich

http://www.w3.org/2001/XMLSchema#string

Laurie Butler

http://www.w3.org/2001/XMLSchema#string

P2860

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach

Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco

Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial

Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques

CDC growth charts: United States

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana

Normative data for bone mass in healthy term infants from birth to 1 year of age.

Intrauterine programming of adult body composition.

Association between bone mass and fractures in children: a prospective cohort study.

Maternal-administered physical activity enhances bone mineral acquisition in premature very low birth weight infants.

P304

996-1003

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIV437

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Linda A. DiMeglio

P577

2015-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278044605

http://www.w3.org/2001/XMLSchema#string

P698

26060285

http://www.w3.org/2001/XMLSchema#string

P921

P932

4551007

http://www.w3.org/2001/XMLSchema#string